BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
11/19/2021 9:32:33 AM | Browse: 1019 | Download: 3104
Publication Name World Journal of Clinical Oncology
Manuscript ID 66208
Country Sweden
ISSN 2218-4333 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright © The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Oncology
Manuscript Type Retrospective Cohort Study
Article Title Real-world evaluation of upfront docetaxel in metastatic castration-sensitive prostate cancer
Manuscript Source Unsolicited Manuscript
All Author List Jenny Isaksson, Henrik Green, Dimitrios Papantoniou, Linn Pettersson, Mats Anden, Johan Rosell, Elisabeth Åvall-Lundqvist and Nils Oskar Elander
ORCID
Author(s) ORCID Number
Jenny Isaksson http://orcid.org/0000-0002-8640-350X
Henrik Green http://orcid.org/0000-0002-8015-5728
Dimitrios Papantoniou http://orcid.org/0000-0001-5472-2322
Linn Pettersson http://orcid.org/0000-0001-9253-5245
Mats Anden http://orcid.org/0000-0002-9298-7724
Johan Rosell http://orcid.org/0000-0002-2342-1348
Elisabeth Åvall-Lundqvist http://orcid.org/0000-0001-7274-1770
Nils Oskar Elander http://orcid.org/0000-0001-9345-0278
Funding Agency and Grant Number
Corresponding Author Nils Oskar Elander, MD, PhD, Doctor, Doctor, Department of Oncology, Department of Biomedical and Clinical Sciences, Linköping University, Linköping University Hospital, Linköping 58185, Sweden. nils.elander@liu.se
Key Words Prostate cancer; Chemotherapy; Docetaxel; Castration sensitive; Metastatic; Real world
Core Tip Two recent trials reported impressive outcomes when upfront docetaxel is added to androgen deprivation therapy in metastatic castration-sensitive prostate cancer (mCSPC). This study presents the outcome and safety of this treatment strategy in a real-world context of all eligible patients in the southeast region of Sweden. While the treatment is toxic in terms of febrile neutropenia and unplanned hospitalizations, the outcome and long-term prognosis appear similar in real life and randomized controlled trial contexts. Further implementation of upfront docetaxel in mCSPC in routine care is encouraged.
Publish Date 2021-11-19 09:32
Citation Isaksson J, Green H, Papantoniou D, Pettersson L, Anden M, Rosell J, Åvall-Lundqvist E, Elander NO. Real-world evaluation of upfront docetaxel in metastatic castration-sensitive prostate cancer. World J Clin Oncol 2021; 12(11): 1009-1022
URL https://www.wjgnet.com/2218-4333/full/v12/i11/1009.htm
DOI https://dx.doi.org/10.5306/wjco.v12.i11.1009
Full Article (PDF) WJCO-12-1009.pdf
Full Article (Word) WJCO-12-1009.docx